Clinical Development and Initial Approval of Novel Immune Checkpoint Inhibitors in Oncology: Insights From a Global Regulatory Perspective-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Clinical Development and Initial Approval of Novel Immune Checkpoint Inhibitors in Oncology: Insights From a Global Regulatory Perspective

Published:2018-09-12 Issue:3 Volume:105 Page:582-597
ISSN:0009-9236
Container-title:Clinical Pharmacology & Therapeutics
language:en
Short-container-title:Clin. Pharmacol. Ther.

Author:

Serrano Philippe¹,Hartmann Markus²,Schmitt Elmar³,Franco Pedro⁴,Amexis Georgios³,Gross Jan³,Mayer‐Nicolai Christine⁵

Affiliation:

1. R&D Regulatory OncologyEMD Serono Research & Development InstituteBillerica Massachusetts USA

2. Ecc‐OncologyTrier Germany

3. R&D Regulatory OncologyMerck KGaA Darmstadt Germany

4. Global Regulatory & Scientific Policy, Merck Serono Europe LtdLondon UK

5. Global Regulatory & Scientific Policy, EMD Serono IncWashington DC USA

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cpt.1123

Reference100 articles.

1. Two Hundred Years of Cancer Research

2. Observations on the Systemic Administration of Autologous Lymphokine-Activated Killer Cells and Recombinant Interleukin-2 to Patients with Metastatic Cancer

3. Hallmarks of Cancer: The Next Generation

4. Oncology Meets Immunology: The Cancer-Immunity Cycle

5. Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Real-world data in drug development strategies for orphan drugs: Tafasitamab in B-cell lymphoma, a case study for an approval based on a single-arm combination trial;Drug Discovery Today;2022-06

2. Prospective, Noninterventional Study of Nivolumab in Real-world Patients With Locally Advanced or Metastatic Non–small Cell Lung Cancer After Prior Chemotherapy (ENLARGE-Lung);Journal of Immunotherapy;2021-12-15

3. HLA Class I Binding of Mutant EGFR Peptides in NSCLC Is Associated With Improved Survival;Journal of Thoracic Oncology;2021-01

4. Melanoma cells can be eliminated by sialylated CD43 × CD3 bispecific T cell engager formats in vitro and in vivo;Cancer Immunology, Immunotherapy;2020-11-23

5. Best practices for detection, assessment and management of suspected immune-mediated liver injury caused by immune checkpoint inhibitors during drug development;Journal of Autoimmunity;2020-11

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3